Daratumumab is a biological drug, a monoclonal antibody directed against the CD38 receptor, present in multiple myeloma tumor cells. However, CD38 is also present in erythrocytes, so this drug also binds to them, which can cause false positives in cross-match test and antibody screening (indirect Coombs).
This can happen up to 6 months after the last administration of the drug.
DaraEx neutralizes the effect of Daratumubab on antibody tests with a simple pretreatment of the erithrocytes, being a quick and effective alternative to the traditional treatment with Dithiothreitol (DTT), which has drawbacks such as the destruction of Kel antigens.
1 vial, 450 ul
Fill in the form below: